

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to

PATENT  
Attorney Docket No.: 021044-000600US 8/22

Assistant Commissioner for Patents  
Washington, D.C. 20231

Op June 21, 2002  
~~TOWNSEND and TOWNSEND and CREW LLP~~

By Jan Jane

RECEIVED

JUL 18 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Masuda et al.

Application No.: 09/998,667

Filed: December 3, 2001

For: TRAC1: MODULATORS OF LYMPHOCYTE ACTIVATION

PETITION TO CORRECT INVENTORSHIP UNDER 37 C.F.R. § 1.48

COPY OF PAPERS  
ORIGINALLY FILED

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Applicants petition under 37 C.F.R. § 1.48 to add Congfen Li as an inventor of the above-identified patent application.

As required by 37 C.F.R. § 1.48, the following are submitted herewith:

- (1) Statement from Congfen Li stating that it was through error without deceptive intent that she was not named as an inventor in the above-identified patent application;
- (2) Written consent from the assignee, Rigel Pharmaceuticals, Inc.
- (3) A supplemental declaration signed by Congfen Li.

07/02/2002 SSESH#1 00000019 201430 09998667

01 FC:122

130.00 CH

Please deduct the petition fee, pursuant to 37 C.F.R. § 1.17(i), from Deposit Account No. 20-1430 of the undersigned. Please charge any additional fees or credit overpayment to the above Deposit Account.

Respectfully submitted,



Annette S. Parent  
Reg. No. 42,058

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: (415) 576-0200/Fax: (415) 576-0300

SF 1349050 v1